TEV 48125

Drug Profile

TEV 48125

Alternative Names: Anti-calcitonin gene-related peptide monoclonal antibody; Anti-CGRP monoclonal antibody; LBR 101; PF 04427429; PF 4427429; RN-307; TEV-48125

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Rinat Neuroscience
  • Developer Rinat Neuroscience; Teva Pharmaceutical Industries
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cluster headache; Migraine

Most Recent Events

  • 11 Nov 2016 Teva Branded Pharmaceutical Products, R&D plans a phase III trial for chronic Cluster headache (Prevention) in USA (NCT02964338)
  • 01 Nov 2016 Phase-III clinical trials in Cluster headache (Prevention) in USA (Parenteral) (Teva Pharmaceutical Pipeline, November 2016)
  • 25 Oct 2016 Teva Branded Pharmaceutical Products, R&D plans a phase III trial for episodic Cluster headache (Prevention) in USA (NCT02945046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top